Short Interest Report: It Seems Zeltiq Aesthetics Incorporated (NASDAQ:ZLTQ) Will Go Up. Just Reported Less Shorted Shares

November 22, 2016 - By Vivian Park   ·   0 Comments

Short Interest Report: It Seems Zeltiq Aesthetics Incorporated (NASDAQ:ZLTQ) Will Go Up. Just Reported Less Shorted Shares

The stock of Zeltiq Aesthetics Incorporated (NASDAQ:ZLTQ) registered a decrease of 5.33% in short interest. ZLTQ’s total short interest was 9.10 million shares in November as published by FINRA. Its down 5.33% from 9.61 million shares, reported previously. With 478,200 shares average volume, it will take short sellers 19 days to cover their ZLTQ’s short positions. The short interest to Zeltiq Aesthetics Incorporated’s float is 23.28%. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has risen 42.96% since April 20, 2016 and is uptrending. It has outperformed by 38.41% the S&P500.

ZELTIQ Aesthetics, Inc. is a medical technology company. The company has a market cap of $1.67 billion. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. It has a 56.78 P/E ratio. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges.

Insitutional Activity: The institutional sentiment increased to 1.47 in 2016 Q2. Its up 0.11, from 1.36 in 2016Q1. The ratio is positive, as 28 funds sold all Zeltiq Aesthetics Inc shares owned while 42 reduced positions. 25 funds bought stakes while 70 increased positions. They now own 43.91 million shares or 2.50% more from 42.84 million shares in 2016Q1.
Bridgeway Capital owns 11,600 shares or 0% of their US portfolio. Fuller & Thaler Asset accumulated 0.2% or 421,597 shares. Gabelli Funds Ltd Liability Corporation last reported 0% of its portfolio in the stock. Wealthtrust has 303 shares for 0% of their US portfolio. Great West Life Assurance Can last reported 4,149 shares in the company. Blackrock holds 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 2,933 shares. Vanguard accumulated 1.57 million shares or 0% of the stock. Riverbridge Partners Limited Liability holds 0.66% or 1.17M shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 795 shares. Fmr Limited Com owns 4.28M shares or 0.02% of their US portfolio. Manufacturers Life Insur The holds 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 24,014 shares. Blackrock Fund Advsrs holds 2.30M shares or 0.01% of its portfolio. Moreover, Royal Commercial Bank Of Canada has 0% invested in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 2,634 shares. Thompson Davis And Com reported 187 shares or 0.01% of all its holdings. St Johns Inv Mgmt Ltd has invested 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ).

Insider Transactions: Since July 11, 2016, the stock had 0 insider purchases, and 19 sales for $27.17 million net activity. Another trade for 3,125 shares valued at $125,000 was sold by Lamm Carl. Foley Mark J sold 50,000 shares worth $1.89 million. $240,123 worth of shares were sold by Sullivan Keith J on Monday, July 11. On Tuesday, August 9 OBOYLE KEVIN C sold $662,500 worth of the stock or 17,500 shares. Hauser Bradley also sold $111,978 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Sunday, September 11. 20,000 Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) shares with value of $781,548 were sold by Garcia Sergio. The insider SCHIFF ANDREW N sold $18.20M.

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) Ratings Coverage

Out of 7 analysts covering Zeltiq Aesthetics (NASDAQ:ZLTQ), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Zeltiq Aesthetics has been the topic of 13 analyst reports since August 3, 2015 according to StockzIntelligence Inc. William Blair maintained Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Wednesday, August 26 with “Outperform” rating. Maxim Group maintained the shares of ZLTQ in a report on Wednesday, October 28 with “Buy” rating. The firm has “Buy” rating given on Thursday, November 10 by Canaccord Genuity. The company was maintained on Tuesday, September 1 by Piper Jaffray. The rating was maintained by JP Morgan with “Neutral” on Tuesday, August 9. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has “Buy” rating given on Wednesday, April 13 by Brean Capital. The stock of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has “Buy” rating given on Friday, January 22 by Griffin Securities. Stifel Nicolaus maintained it with “Buy” rating and $52 target price in Wednesday, September 21 report. Leerink Swann maintained the shares of ZLTQ in a report on Wednesday, October 28 with “Outperform” rating.

ZLTQ Company Profile

ZELTIQ Aesthetics, Inc., incorporated on March 22, 2005, is a medical technology company. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Firm sell its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system.

More important recent Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) news were published by: Fool.com which released: “Why Zeltiq Aesthetics Inc. Is Soaring Today” on November 10, 2016, also Nasdaq.com published article titled: “Earnings Reaction History: ZELTIQ Aesthetics, Inc., 40.0% Follow-Through …”, Fool.com published: “Zeltiq Aesthetics Earnings: Keeping Up Appearances” on August 08, 2016. More interesting news about Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) was released by: Fool.com and their article: “1 Wall Street Pro Heats Up on CoolSculpting Artist Zeltiq Aesthetics” with publication date: September 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>